Drugs / HYDROMETHYLTHIONINE
HYDROMETHYLTHIONINE
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01626391 | Sep 2012 → Mar 2013 | Alzheimer disease | TauRx Therapeutics Ltd | Terminated | No outcome recorded |
| Phase 35 trials · 1 missed | ||||||
| Phase 3 | NCT03446001 | Dec 2017 → Mar 2022 | Alzheimer disease | TauRx Therapeutics Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02245568 | Aug 2014 → May 2017 | Alzheimer disease, behavioral variant of frontotemporal dementia | TauRx Therapeutics Ltd | Terminated | No outcome recorded |
| Phase 3 | NCT01626378 | May 2013 → Feb 2016 | behavioral variant of frontotemporal dementia | TauRx Therapeutics Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01689246 | Jan 2013 → Nov 2015 | Alzheimer disease | TauRx Therapeutics Ltd | Completed | Missed primary |
| Phase 3 | NCT01689233 | Oct 2012 → May 2016 | Alzheimer disease | TauRx Therapeutics Ltd | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03539380 | — | Alzheimer disease | TauRx Therapeutics Ltd | Available | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-03-07 | TauRx Therapeutics Ltd | Two year sustained cognitive benefits of Hydromethylthionine Mesylate (HMTM) indicated by TauRx’s LUCIDITY trial taurx.com ↗ |
| 2023-07-16 | TauRx Therapeutics Ltd | TauRx’s hydromethylthionine mesylate (HMTM) demonstrates significant reduction in neurodegeneration in Alzheimer’s Disease (AD) taurx.com ↗ |
| 2023-07-16 | TauRx Therapeutics Ltd | TauRx’s hydromethylthionine mesylate (HMTM) demonstrates significant reduction in neurodegeneration in Alzheimer’s Disease (AD) taurx.com ↗ |
| 2020-03-04 | TauRx Therapeutics Ltd | Preclinical study shows how commonly prescribed drugs for Alzheimer’s disease interfere with the activity of the tau aggregation inhibitor hydromethylthionine taurx.com ↗ |
| 2019-11-26 | TauRx Therapeutics Ltd | New study shows a minimum dose of hydromethylthionine could slow cognitive decline and brain atrophy in mild-to-moderate Alzheimer’s disease taurx.com ↗ |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HYDROMETHYLTHIONINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL549963 ↗ |
| Known as | Hidrometiltionina | ChEMBL registry synonym — accepted as the source's own label CHEMBL549963 ↗ |
| Known as | HYDROMETHYLTHIONINE MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL549963 ↗ |
| Known as | Leuco-methylthioninium Bis(Hydromethanesulfonate) | “Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)” NCT02245568 ↗ |
| Known as | Leuco-methylthioninium dimesylate | ChEMBL registry synonym — accepted as the source's own label CHEMBL549963 ↗ |
| Known as | Leucomethylene blue | ChEMBL registry synonym — accepted as the source's own label CHEMBL549963 ↗ |
| Known as | Leucomethylene blue bismesylate | ChEMBL registry synonym — accepted as the source's own label CHEMBL549963 ↗ |
| Known as | Leucomethylene blue dimesylate | ChEMBL registry synonym — accepted as the source's own label CHEMBL549963 ↗ |
| Known as | Leukomethylene blue | ChEMBL registry synonym — accepted as the source's own label CHEMBL549963 ↗ |
| Known as | LMTM | “Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)” NCT02245568 ↗ |
| Known as | Lmtx | ChEMBL registry synonym — accepted as the source's own label CHEMBL549963 ↗ |
| Known as | Methylene blue leuco form | ChEMBL registry synonym — accepted as the source's own label CHEMBL549963 ↗ |
| Known as | Reduced methylene blue | ChEMBL registry synonym — accepted as the source's own label CHEMBL549963 ↗ |
| Known as | TRx0237 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03539380 ↗ |
| Modality | Small molecule | — CHEMBL549963 ↗ |
| Route | Oral | “Oral TRx0237 4-mg tablets administered twice daily” NCT03446001 ↗ |